🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

First People's Hospital of Hangzhou clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with First People's Hospital of Hangzhou as lead sponsor. Synced 26 Sep 2026
13Current trials
8Recruiting now
3Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

First People's Hospital of Hangzhou is the lead sponsor of 13 current clinical trials in our China register. 8 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Amoxicillin, Tegoprazan and Vonoprazan. The most-studied condition is Motor Neuron Disease (MND).

ClinicalTrials.gov trials by status

  • Recruiting862%
  • Not yet open431%
  • By invitation18%

Trials by phase

  • Observational538%
  • Not applicable323%
  • Phase 4215%
  • Phase 2215%
  • Phase 2/318%
01

Clinical trials sponsored by First People's Hospital of Hangzhou

13 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
The Study Evaluating the Improvement of Nutritional Status and Frailty With Silkworm Pupa Powder Among Patients With Motor Neuron Disease
NCT06765499 · ClinicalTrials.gov ↗ · Motor Neuron Disease (MND), Amyotrophic Lateral Sclerosis (ALS)
Not applicable Recruiting 2025-03 China
Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell Carcinoma
NCT07207278 · ClinicalTrials.gov ↗ · Signet Ring Cell Carcinoma of the Lung
Observational Recruiting 2025-09 China
Electroacupuncture Regulation of Immune Cells in Herpes Zoster
NCT06643247 · ClinicalTrials.gov ↗ · Herpes Zoster, Electroacupuncture, Immune
Not applicable Recruiting 2024-11 China
Head-to-head Study of Tegoprazan 50 mg BID Plus Amoxicillin 1 g TID vs. Vonoprazan 20 mg BID Plus Amoxicillin 1 g TID for H. Pylori Eradication
NCT07242456 · ClinicalTrials.gov ↗ · Helicobacter Pylori Infection
Phase 2/3 Recruiting 2025-02 China
Chemotherapy Plus Immunotherapy Combined With SBRT as Neoadjuvant Therapy for Patients With Resectable NSCLC
NCT06718309 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer
Phase 2 Recruiting 2024-04 China
Study on Clostridium Difficile Infection in Infants
NCT06703918 · ClinicalTrials.gov ↗ · Clostridium Difficile Infection
Observational Recruiting 2024-07 China
Study of Tenofovir Alafenamide in HBV-Infected Pregnant Women
NCT05853718 · ClinicalTrials.gov ↗ · Chronic Hepatitis b, Tenofovir Alafenamide Fumarate
Phase 4 Recruiting 2021-05 China
The Safety and Efficiency of Endovascular Treatment of Acute or Subacute Thromboembolic Occlusions of Lower Extremity.
NCT04861506 · ClinicalTrials.gov ↗ · Thromboembolic Disease, Lower Extremity Problem, Endovascular Treatment
Observational Recruiting 2021-04 China
Tegoprazan Plus Amoxicillin BID vs TID Regimens for H. Pylori Eradication(Frequency Adjusted Same-dose Therapy for H. Pylori)
NCT07242443 · ClinicalTrials.gov ↗ · HELICOBACTER PYLORI INFECTIONS
Phase 4 Not yet open 2025-11 China
Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG)
NCT07507825 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML)
Phase 2 Not yet open 2026-03 China
Clinical Research on the Application of Single-channel Uterine Fibroid Morcellation System in Laparoscopic Myomectomy
NCT06442605 · ClinicalTrials.gov ↗ · Leiomyoma, Uterine
Not applicable Not yet open 2024-06 China
The Biobank Integrating Longitudinal ERCP Within a Prospective Chronic Pancreatitis Cohort
NCT07770412 · ClinicalTrials.gov ↗ · Chronic Pancreatitis
Observational Not yet open 2026-08 China
Safety and Efficacy of Chocolate Balloon Catheter in Peripheral Arterial Disease (CHOCO-PAD)
NCT06933992 · ClinicalTrials.gov ↗ · Peripheral Arterial Disease
Observational By invitation 2025-07 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in First People's Hospital of Hangzhou trials

3 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in First People's Hospital of Hangzhou trials

20 conditions
Motor Neuron Disease (MND)1Amyotrophic Lateral Sclerosis (ALS)1Signet Ring Cell Carcinoma of the Lung1Herpes Zoster1Electroacupuncture1Immune1Peripheral Arterial Disease1HELICOBACTER PYLORI INFECTIONS1Helicobacter Pylori Infection1Non-Small Cell Lung Cancer1Acute Myeloid Leukemia (AML)1Leiomyoma, Uterine1Clostridium Difficile Infection1Chronic Hepatitis b1Tenofovir Alafenamide Fumarate1Chronic Pancreatitis1Thromboembolic Disease1Lower Extremity Problem1Endovascular Treatment1Safety Issues1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China138

A trial with sites in more than one country appears in each of those registers.

05

Questions about First People's Hospital of Hangzhou trials

How many clinical trials does First People's Hospital of Hangzhou sponsor?

First People's Hospital of Hangzhou is the lead sponsor of 13 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are First People's Hospital of Hangzhou trials recruiting?

Yes. 8 of its 13 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is First People's Hospital of Hangzhou testing?

Its current trials name 3 drugs and biologicals as interventions. The most frequent are Amoxicillin (2), Tegoprazan (2) and Vonoprazan (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.